<DOC>
	<DOCNO>NCT00835770</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety profile BG00012 ( dimethyl fumarate ) . Secondary objective study evaluate long-term efficacy BG00012 use clinical endpoint disability progression , evaluate long-term effect BG00012 multiple sclerosis ( MS ) brain lesion magnetic resonance imaging ( MRI ) scan participant MRI scan part Studies 109MS301 ( NCT00420212 ) 109MS302 ( NCT00451451 ) evaluate long-term effect BG00012 health economics assessment visual function test .</brief_summary>
	<brief_title>BG00012 Monotherapy Safety Efficacy Extension Study Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>The initial BG00012 dosage extension study ( 240 mg BID 240 mg TID ) use Phase 3 Studies 109MS301 ( NCT00420212 ) 109MS302 ( NCT00451451 ) . Subsequent initiation study , BG00012 approve several country treatment MS dose 240 mg BID . For reason , participant continue study receive currently market dose 240 mg BID .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Subjects participate complete per protocol previous BG00012 clinical study 109MS301 ( NCT00420212 ) 109MS302 ( NCT00451451 ) . Key Any significant change medical history 109MS301 109MS302 would exclude subject 's participation previous study . Subjects 109MS301 109MS302 discontinue oral study treatment due AE due reason protocoldefined relapse/disability progression . Subjects 109MS301 109MS302 discontinue study treatment due disability progression relapse follow modify visit schedule Week 96 . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>relapse</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>remit</keyword>
	<keyword>oral</keyword>
</DOC>